Nurocor is listed as a #SampleVendor in the 2022 Gartner® Hype Cycle™ for Life Science Clinical Development

by Jan 26, 2023

Nurocor is listed as a #SampleVendor in the 2022 Gartner® Hype Cycle™ for Life Science Clinical Development for two categories: Clinical Data Analytics Platforms and Structured Content and Component Authoring.

“Nurocor is proud to be acknowledged/listed in the two categories of the Gartner® Hype Cycle™ for Life Science Clinical Development as we believe it is a recognition of our unique capability to seamlessly connect the planning stage of a clinical trial to the operational stage via a fully digitalized clinical development process that starts at the protocol.” said Alex Lazar, President & CEO, Nurocor. “Nurocor Clinical Platform represents a transformational change and turns digital transformation into accelerated clinical development.”

The Hype Cycle

Gartner says “CIOs, IT leaders and business professionals in life sciences are looking for new innovative and differentiating capabilities while driving operational effectiveness at scale. This Hype Cycle explores innovative technologies that are specifically relevant to life science clinical development programs in the pharmaceutical, biotechnology, diagnostics, medical device, research institution and contract research sectors. The ongoing need to support new products and rapidly drive them to commercialization leads to continual disruption and

Structured Content and Component Authoring

In Gartner definition “Structured content authoring (SCA) and component-based authoring (CBA) consist of technologies and processes for managing data and content captured in manufacturing, regulatory, quality, clinical and other activities used in life science regulatory filings.” Gartner explains that this technology is important because “SCA supersedes traditional document-based approaches, where content is often inaccessible over time or redundantly captured. It decomposes documents, data and other content into discrete components that can be flexibly reused and assembled into different end requirements, and change managed, resulting in greater productivity and control for life science companies operating in complex, global regulatory environments.” Gartner identifies the business impact as “SCA and CBA improve regulatory compliance, speed up cycle times in protocol development, make regulatory filings smooth, increase productivity in content management, and improve collaboration across global clinical and regulatory groups. They also enable distributed authoring in parallel, improving timelines, and allow report components to be reused and overall report development to become less of an individual chore.”

Clinical Data Analytics Platforms

In Gartner definition, “Clinical data analytics platforms bring modern data and analytics approaches to clinical trial data processes, expanding on existing clinical data repository solutions and data science laboratories by integrating them under a modern logical data warehouse architecture. They expand the capabilities of existing solutions involved in intake, processing, and management of clinical and operational data from source systems and enable end-user analytics point solutions supporting trial operations.” Gartner goes on to say, “With the upward trend of more complex trial types, these solutions assist in eliminating data silos, supporting trial builds, normalizing metadata and enabling integrated insights generation during trial conduct.” Gartner identifies as one of the benefits, “Clinical data library management and study setup optimization”

GARTNER Disclaimer:

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. The Gartner document is available upon request from Nurocor.

Get Your Complimentary Gartner Report